Resistance

Resistance in your own words

• 

  My life with HIV

  I was born in Zambia in 1973 and came to England in April 1994 to live with my cousin to help her look after her...

  From:In your own words

Resistance news from aidsmap

• New integrase inhibitor dolutegravir helps treatment-experienced people on failing therapy

  The next-generation integrase inhibitor dolutegravir proved more beneficial than raltegravir (Isentress) for treatment-experienced people with resistance to two or more antiretroviral drug classes, researchers reported in a poster presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week ...

  10 March 2013 | Liz Highleyman

• Can people with resistant HIV omit NRTIs when switching from a failing regimen?

  Omitting nucleoside reverse transcriptase inhibitors (NRTIs) when switching from a non-suppressive regimen to a new combination with at least two active agents can reduce pill burden and side-effects without compromising effectiveness, researchers reported yesterday at the 20th Conference on Retroviruses and Opportunistic Infections ...

  07 March 2013 | Liz Highleyman

• Nigeria: Drug resistance data show merits of using tenofovir in first-line ART regimens

  People living with HIV in Nigeria, at high risk for virological failure, on a tenofovir (TDF)-based first-line regimen, had fewer nucleoside reverse transcriptase inhibitor (NRTI) drug-resistant mutations and more fully active NRTI drug options for second-line treatment, researchers report ...

  23 January 2013 | Carole Leach-Lemens

• Prevalence of drug-resistant HIV has fallen dramatically among antiretroviral-experienced patients in Western Europe

  There has been a significant fall in the proportion of HIV-positive people in Western Europe with experience of HIV treatment who have resistance to antiretroviral drugs, investigators report in the online edition of the Journal of ...

  22 January 2013 | Michael Carter

• Any reduction in viral load has immunologic benefits for people with HIV who have triple-class treatment failure

  HIV therapy that achieves even modest reductions in viral load can have profound immunological benefits for people with triple-class treatment failure, European investigators report in the online edition of the Journal of Infectious Diseases. “There is close to a linear ...

  08 January 2013 | Michael Carter

• New fixed-dose combination pills measure up to Atripla - corrected version*

  Several studies, or updates of studies, comparing newer against older drug regimens were presented at the Eleventh International Congress on Drug Therapy in HIV Infection last week. Amongst them were the 48-week results from the STAR study, an open-label ...

  20 November 2012 | Gus Cairns

• Long-acting fusion inhibitor albuvirtide looks promising in early studies

  A new fusion inhibitor that prevents HIV entry into cells showed potent antiviral activity in early clinical studies and has a long half-life, suggesting it may be suitable for once-weekly dosing, Chinese researchers reported yesterday at the 52nd Interscience Conference ...

  11 September 2012 | Liz Highleyman

• Dolutegravir matches raltegravir for people starting treatment

  The novel integrase inhibitor dolutegravir worked as well as raltegravir (Isentress) at 48 weeks for treatment-naive people in the Phase III SPRING-2 study, according to a late-breaker presentation Thursday at the 19th International AIDS Conference (AIDS 2012) in Washington ...

  27 July 2012 | Liz Highleyman

• High levels of adherence reached in two PrEP studies, but resistance cases show need for rigorous testing before prescribing

  Two studies of pre-exposure prophylaxis (PrEP) in heterosexuals in Africa, both of which reported significant efficacy in preventing HIV infection last year, published their final results in the New England Journal of Medicine last week. Drug level tests found that ...

  20 July 2012 | Gus Cairns

• HIV treatment breaks lead to drug resistance in the female genital tract

  Antiretroviral treatment interruptions of 48 hours or more are associated with the emergence of resistant strains of HIV in the female genital tract, investigators report in the online edition of the Journal of Acquired Immune Deficiency Syndromes. The study ...

  24 May 2012 | Michael Carter

More news

Resistance news selected from other sources

• Computer models predict how patients will respond to HIV drugs

  Results of a new study demonstrate that computer models can predict how HIV patients whose drug therapy is failing will respond to a new treatment. Crucially for patients in poorer countries, the models do not require the results of expensive drug resistance tests to make their predictions. The study also showed that the models were able to identify alternative drug combinations that were predicted to work in cases where the treatment used in the clinic had failed, suggesting that their use could avoid treatment failure.

  14 March 2013 | Eurekalert Inf Dis

• Wide US Study Finds 16% With Newly Diagnosed HIV Carry Resistant Virus

  Just over 16% of US residents newly diagnosed with HIV infection in 10 metropolitan areas or states carried antiretroviral-resistant virus, according to a CDC study spanning the years 2007 to 2010.

  11 March 2013 | NATAP

• Transmission of Resistant HIV Steady

  The rate of drug-resistant HIV transmission in the U.S. appears to be holding steady, according to the most recent CDC figures.

  07 March 2013 | MedPage Today HIV/AIDS

• Updated HIV Treatment Guidelines Include Stronger Recommendation for Acute Infection

  Among the key changes are additional information about the most recently approved antiretroviral agents and a recommendation that newly infected people with HIV should be offered combination ART. The guidelines continue to recommend treatment for all people with HIV, both to reduce the risk of disease progressionand for the prevention of HIV transmission.

  15 February 2013 | HIVandHepatitis.com

• Updated U.S. DHHS guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents

  New recommendations on drug-resistance testing, genotypic tropism assays, starting treatment, acute infection, pregnancy and interactions.

  15 February 2013 | AIDSinfo

• Redefining Expanded Access Programs for patients with MDR-HIV

  It is time to create a new paradigm to break the vicious cycle of single drug access that has failed these patients.

  04 December 2012 | GMHC Treatment Issues

• Raltegravir-resistant HIV stays susceptible to dolutegravir in lab

  HIV resistant to the integrase inhibitor raltegravir and isolated from patients taking a failing raltegravir regimen remained largely susceptible to the integrase inhibitor dolutegravir in phenotypic susceptibility testing. Raltegravir-resistant virus carrying a mutation at position Q148 had more reduced susceptibility to dolutegravir than isolates with other raltegravir mutations.

  13 November 2012 | International AIDS Society

• The genetics of HIV-1 resistance

  New research has examined the genetic footprint that drug resistance causes in HIV and found compensatory polymorphisms that help the resistant virus to survive.

  08 October 2012 | Science Daily

• In heterosexuals, transmitted HIV strains often resemble original infecting virus

  A new study has found that even though HIV diversifies widely within infected individuals over time, the virus strains that ultimately are passed on through heterosexual transmission often resemble the strain of virus that originally infected the transmitting partner. Learning the characteristics of these preferentially transmitted HIV strains may help advance HIV prevention efforts, particularly with regard to an HIV vaccine, according to the scientists who conducted the study.

  25 September 2012 | Eurekalert Inf Dis

• Mutation breaks HIV's resistance to drugs

  The human immunodeficiency virus (HIV) can contain dozens of different mutations, called polymorphisms. In a recent study an international team of researchers found that one of those mutations, called 172K, made certain forms of the virus more susceptible to treatment. Soon, doctors will be able to use this knowledge to improve the drug regimen they prescribe to HIV-infected individuals.

  14 September 2012 | Science Daily

More news